Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
RESEARCH TOOLSreports
GLUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.21 - $12.40
Previous CloseN/A
Volume283.19K
Average Volume (3M)749.68K
Market Cap
$402.41M
Enterprise Value$236.17M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Mar 13, 2025EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding61,436,740
10 Day Avg. Volume394,360
30 Day Avg. Volume749,685
Standard Deviation0.28
R-Squared0.06
Alpha-0.00746
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.87
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.96
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$15.50Price Target Upside133.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Monte Rosa Therapeutics News
PremiumCompany Announcements
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength
PremiumCompany Announcements
Monte Rosa Highlights Promising Results in Cancer Study---
Bulls Say, Bears Say
Bulls Say
Collaboration AgreementGLUE announced a collaborative agreement with Novartis to develop its first in class VAV1-degrader program MRT-6160.
Financial BackingGLUE will receive an upfront payment of $150M as well as total milestone payments of up to $2.1B.
Bears Say
Pipeline LimitationsThe remainder of GLUE's pipeline remains early, with no expectations for significant stock-moving clinical data from other pipeline projects.
---
Ownership Overview
22.89% Insiders
20.99% Mutual Funds
39.96% Other Institutional Investors
7.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $3.21 and its highest was $12.40 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $402.41M.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 20 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.475 by $0.185.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is 0.18.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 61,436,740 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.475. Following the earnings report the stock price went up 0.847%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
---
Monte Rosa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (133.79% Upside)
$15.50 (133.79% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.24%
12-Months-Change
Fundamentals
Return on Equity
-61.23%
Trailing 12-Months
Asset Growth
24.98%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
---
GLUE Stock 12 Month Forecast
Average Price Target
$15.50
▲(133.79% Upside)
Technical Analysis
Fate Therapeutics
―
Ultragenyx Pharmaceutical
―
Arvinas Holding Company
―
Revolution Medicines
―
Kymera Therapeutics
―
Best Analysts Covering GLUE
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+33.63%
reiterated a buy rating 3 months ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +33.63% per trade.
---